预约演示
AbbVie drops midphase psoriasis prospect over preclinical toxicology data, sinking partner's stock
2022-10-31
If AbbVie had continued the program, Inventiva could have pocketed up to 31 million euros in milestones.
AbbVie and Inventiva discovered the ROR inverse agonist as part AbbVie012psoriasisation intended to yield compounds that suppress a larger set of inflammatory cytokines than currently available biInventivaor the treatment of psoriasis. The partnership spawned cedirogant, a molecule that AbbVie took into a phase 2b trial in moderate to severe psoriasis late last year.
AbbVieust mInventivago in the study,ROR inverse agonistROR inversescheduled to end in March 2023, AbbVie has pulled the plug in response to preclinical data. The Big Pharma said the decision to stop development of the asset was driven by new fipsoriasisserved in its preclinical cedirogantxicology study.AbbViepsoriasis
Shares in Inventiva fell 21% in premarket trading on Monday to 4.54 euros ($4.5AbbViethe wake of the news. Through to the end of last year, AbbVie paid 16.4 million euros ($16.3 million) in research funding and 13 million euros ($12.9 million) in milestone payments. An additional 4 million euro milestone, tied to the start of the phase 2b, followed in January. If AbbVie had continued the program, Inventiva could have pocketed up to 31 million euros ($30.8 million) in milestones linked to the psoriasis program.
While AbbVInventivaon has ended Inventiva’s hopes of future paydays, the French biotech’s cash runway is unaffected by the termination of ceAbbVient development. The company continues to expect its existing cash reserves, plus an anticipated $12 million upfront payment from Sino Biopharm and 25 million euros ($24.8 million) from its EIB credit facility, to see it AbbVieh to the fourth quarter of nInventivapsoriasis
The caAbbVieway is set to end beInventivantiva delivers phase 3 data on its pan-PPAR agonist lanifibranor in nonalcoholic steatohepatitis.cedirogant expects to have to wait until the back half of 2025 to see data from the phase 3 trial, although two midphase studies that areSino Biopharmmolecule in patients with Type 2 diabetes are sEIBduled to report results next year.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。